MLL
DRNA

Moody Lynn & Lieberson’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Moody Lynn & Lieberson’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-65,515
Closed -$1.44M – 211
2019
Q4 		$1.44M Buy
+65,515
New +$1.32M 0.14% 100

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Moody Lynn & Lieberson's DRNA Position: Q1 2020 in Review

Moody Lynn & Lieberson sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2020, closing a stake of 65,515 shares — an estimated $1.44M sold.

Moody Lynn & Lieberson first reported a position in DRNA in Q4 2019 and held it in 1 quarter. The position peaked at $1.44M in Q4 2019. 144 funds tracked by Wall St. Rank hold DRNA as of Q1 2020.

  • Moody Lynn & Lieberson reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 65,515 Dicerna Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.44M.
  • Moody Lynn & Lieberson first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Moody Lynn & Lieberson's Dicerna Pharmaceuticals, Inc. position peaked at $1.44M in Q4 2019.
  • 144 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2020.

Based on Moody Lynn & Lieberson's 13F filing for Q1 2020, filed 30 Apr 2020.